Literature DB >> 16424388

Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1.

Joshua Arnold1, Brenda Yamamoto, Min Li, Andrew J Phipps, Ihab Younis, Michael D Lairmore, Patrick L Green.   

Abstract

Natural antisense viral transcripts have been recognized in retroviruses, including human T-cell leukemia virus type 1 (HTLV-1), HIV-1, and feline immunodeficiency virus (FIV), and have been postulated to encode proteins important for the infection cycle and/or pathogenesis of the virus. The antisense strand of the HTLV-1 genome encodes HBZ, a novel nuclear basic region leucine zipper (b-ZIP) protein that in overexpression assays down-regulates Tax oncoprotein-induced viral transcription. Herein, we investigated the contribution of HBZ to HTLV-1-mediated immortalization of primary T lymphocytes in vitro and HTLV-1 infection in a rabbit animal model. HTLV-1 HBZ mutant viruses were generated and evaluated for viral gene expression, protein production, and immortalization capacity. Biologic properties of HBZ mutant viruses in vitro were indistinguishable from wild-type HTLV-1, providing the first direct evidence that HBZ is dispensable for viral replication and cellular immortalization. Rabbits inoculated with irradiated cells expressing HTLV-1 HBZ mutant viruses became persistently infected. However, these rabbits displayed a decreased antibody response to viral gene products and reduced proviral copies in peripheral blood mononuclear cells (PBMCs) as compared with wild-type HTLV-1-infected animals. Our findings indicated that HBZ was not required for in vitro cellular immortalization, but enhanced infectivity and persistence in inoculated rabbits. This study demonstrates that retroviruses use negative-strand-encoded proteins in the establishment of chronic viral infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424388      PMCID: PMC1895283          DOI: 10.1182/blood-2005-11-4551

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Tax-dependent stimulation of G1 phase-specific cyclin-dependent kinases and increased expression of signal transduction genes characterize HTLV type 1-transformed T cells.

Authors:  K Haller; T Ruckes; I Schmitt; D Saul; E Derow; R Grassmann
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-01       Impact factor: 2.205

Review 2.  Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B.

Authors:  K T Jeang
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

3.  Natural antisense transcripts are detected in different cell lines and tissues of cats infected with feline immunodeficiency virus.

Authors:  S Briquet; J Richardson; C Vanhée-Brossollet; C Vaquero
Journal:  Gene       Date:  2001-04-18       Impact factor: 3.688

4.  Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo.

Authors:  J T Bartoe; B Albrecht; N D Collins; M D Robek; L Ratner; P L Green; M D Lairmore
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription.

Authors:  Gilles Gaudray; Frederic Gachon; Jihane Basbous; Martine Biard-Piechaczyk; Christian Devaux; Jean-Michel Mesnard
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax.

Authors:  Y Liu; Y Wang; M Yamakuchi; S Masuda; T Tokioka; S Yamaoka; I Maruyama; I Kitajima
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

7.  Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).

Authors:  Y Hatta; H P Koeffler
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

8.  Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein.

Authors:  Kerstin Haller; Yalin Wu; Elisabeth Derow; Iris Schmitt; Kuan-Teh Jeang; Ralph Grassmann
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

9.  Tax and overlapping rex sequences do not confer the distinct transformation tropisms of human T-cell leukemia virus types 1 and 2.

Authors:  Jianxin Ye; Li Xie; Patrick L Green
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  HTLV-I antisense transcripts initiating in the 3'LTR are alternatively spliced and polyadenylated.

Authors:  Marie-Hélène Cavanagh; Sébastien Landry; Brigitte Audet; Charlotte Arpin-André; Patrick Hivin; Marie-Eve Paré; Julien Thête; Eric Wattel; Susan J Marriott; Jean-Michel Mesnard; Benoit Barbeau
Journal:  Retrovirology       Date:  2006-03-02       Impact factor: 4.602

View more
  107 in total

1.  The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30(II) mRNA.

Authors:  Gunjan Choudhary; Lee Ratner
Journal:  Virology       Date:  2010-12-21       Impact factor: 3.616

2.  Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits.

Authors:  Valerio W Valeri; Anna Hryniewicz; Vibeke Andresen; Kathy Jones; Claudio Fenizia; Izabela Bialuk; Hye Kyung Chung; Risaku Fukumoto; Robyn Washington Parks; Maria Grazia Ferrari; Christophe Nicot; Valentina Cecchinato; Frank Ruscetti; Genoveffa Franchini
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

3.  Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Authors:  Priya Kannian; Han Yin; Rami Doueiri; Michael D Lairmore; Soledad Fernandez; Patrick L Green
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein.

Authors:  Sara Calattini; Sébastien Alain Chevalier; Renan Duprez; Philippe Afonso; Alain Froment; Antoine Gessain; Renaud Mahieux
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice.

Authors:  Paola Miyazato; Jun-ichirou Yasunaga; Yuko Taniguchi; Yoshio Koyanagi; Hiroaki Mitsuya; Masao Matsuoka
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

6.  Detection and quantitation of HTLV-1 and HTLV-2 mRNA species by real-time RT-PCR.

Authors:  Min Li; Patrick L Green
Journal:  J Virol Methods       Date:  2007-03-06       Impact factor: 2.014

7.  Natural antisense transcripts of UL123 packaged in human cytomegalovirus virions.

Authors:  Cui-Qing Yang; Ling-Feng Miao; Xing Pan; Cong-Cong Wu; Simon Rayner; Edward S Mocarski; Han-Qing Ye; Min-Hua Luo
Journal:  Arch Virol       Date:  2013-07-25       Impact factor: 2.574

8.  Human T lymphotropic virus type 1 regulatory and accessory gene transcript expression and export are not rex dependent.

Authors:  Min Li; Priya Kannian; Han Yin; Matthew Kesic; Patrick L Green
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

Review 9.  Implication of the HTLV-I bZIP factor gene in the leukemogenesis of adult T-cell leukemia.

Authors:  Yorifumi Satou; Masao Matsuoka
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

10.  Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription.

Authors:  Marilène Halin; Estelle Douceron; Isabelle Clerc; Chloé Journo; Nga Ling Ko; Sébastien Landry; Edward L Murphy; Antoine Gessain; Isabelle Lemasson; Jean-Michel Mesnard; Benoît Barbeau; Renaud Mahieux
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.